Orlandi, Ester Maria <br/><br/>
Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.  [electronic resource] 

 -  Leukemia & lymphoma  07 2017 
 - 1764-1766 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428194.2016.1260127  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Female<br/>Hepatitis B--complications<br/>Hepatitis B virus--drug effects<br/>Humans<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--complications<br/>Male<br/>Middle Aged<br/>Protein Kinase Inhibitors--adverse effects<br/>Risk Assessment<br/>Virus Activation--drug effects<br/>Young Adult